TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Interaction Details
01. General Information
Pair Name Toosendanin, Irinotecan
Phytochemical Name Toosendanin (PubChem CID: 9851101 )
Anticancer drug Name Irinotecan (PubChem CID: 60838 )
Structure of
Phytochemical
2D-img
Download
2D MOL 3D MOL
Structure of
Anticancer Drug
2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 221
Pair Name Toosendanin, Irinotecan
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->Autophagy
Gene Regulation Up-regulation Expression CASP3 hsa836
Down-regulation Expression CTSB hsa1508
Down-regulation Expression CTSD hsa1509
In Vitro Model MDA-MB-231 Breast adenocarcinoma Homo sapiens (Human) CVCL_0062
MDA-MB-436 Invasive breast carcinoma Homo sapiens (Human) CVCL_0623
In Vivo Model MDA-MB-231 cells stably expressing RFP-GFP-LC3 were suspended in a 1:1 ratio in serum-free DMEM medium with a matrigel basement membrane matrix and inoculated subcutaneously (5×10⁶/site) in the right armpit.
Result The data showed that TSN blocked 7-ethyl-10-hydroxycamptothecin (SN-38)/irinotecan-induced protective autophagy, and significantly induced apoptosis in TNBC cells and tumor xenograft models when compared to SN-38/irinotecan alone group.
03. Reference
No. Title Href
1 Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy. Chin Med. 2022 May 6;17(1):55. doi: 10.1186/s13020-022-00605-8. Click
It has been 46934 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP